创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology iHuPDX Model: A New Milestone in Personalized Medicine

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-06 15:17
  • Views:

(Summary description)With the deepening of medical research, traditional cancer research and treatment methods can no longer meet the growing demand for individualization. Against this backdrop, the iHuPDX (Individualized Human Patient-Derived Xenograft) model of InnoModels Biotechnology has emerged, bringing a new perspective and solution to the field of cancer research and treatment.

InnoModels Biotechnology iHuPDX Model: A New Milestone in Personalized Medicine

(Summary description)With the deepening of medical research, traditional cancer research and treatment methods can no longer meet the growing demand for individualization. Against this backdrop, the iHuPDX (Individualized Human Patient-Derived Xenograft) model of InnoModels Biotechnology has emerged, bringing a new perspective and solution to the field of cancer research and treatment.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-06 15:17
  • Views:
Information

With the deepening of medical research, traditional cancer research and treatment methods can no longer meet the growing demand for individualization. Against this backdrop, the iHuPDX (Individualized Human Patient-Derived Xenograft) model of InnoModels Biotechnology has emerged, bringing a new perspective and solution to the field of cancer research and treatment.
The iHuPDX model is a xenograft technology based on individual patient's tumor cells, which forms individualized transplanted tumors by collecting patient's cancer tissue samples and transplanting them into animals such as mice. This technology can more realistically simulate the tumor environment in the patient's body, providing important support for precision medicine.
First, the iHuPDX model is highly individualized. Each patient's tumor has its own unique biological characteristics and heterogeneity, and the iHuPDX model is able to preserve these original features, enabling researchers to gain a more comprehensive understanding of a patient's tumor characteristics. This highly individualized model provides an important experimental tool for precision medicine and helps develop more personalized treatment plans.
Second, the iHuPDX model can be used to predict drug response. Due to the highly individualized nature of the model, researchers can use the iHuPDX model to test the response of different drugs to a specific patient's tumor. This provides a powerful tool for personalized treatment plan development and is expected to improve treatment success rates. Through drug sensitivity experiments, doctors can predict a patient's response to different drugs so that they can choose the most appropriate treatment plan for the patient.

 


In addition, the iHuPDX model provides a new perspective for cancer research. Through in-depth study of tumor heterogeneity among different patients, researchers can better understand the diversity and complexity of cancer. This provides important information for the development of individualized therapeutic strategies and helps to advance cancer treatment.
The iHuPDX model from InnoModels Biotechnology has other advantages. First, it retains the heterogeneity of the original tumor tissue, making the model closer to the actual patient. Second, the model has good stability and growth rate, providing a reliable experimental platform for drug development and efficacy assessment. Finally, InnoModels Biotechnology has a stable platform of humanized immune system mouse model (HIS) and human tumor xenograft platform (PDX), which provides comprehensive technical support for tumor and tumor immunopharmacodynamics research.
In conclusion, the iHuPDX model from InnoModels Biotechnology has revolutionized the field of cancer research and treatment. It establishes a highly individualized disease model based on individual patient's tumor cells, providing an important experimental tool for precision medicine. By predicting drug response and studying tumor heterogeneity in depth, the iHuPDX model is expected to increase the success rate of treatment and advance cancer therapy. The continuous innovation and efforts of InnoModels Biotechnology in the field of personalized medicine provide more precise and personalized solutions for medical research and drug development, and bring more hope and possibilities to tumor patients.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司